Protect Confidential Information in Investigational Drug Submissions Blog Protect Confidential Information in Investigational Drug Submissions 2025年3月20日 Health regulatory agencies require pharmaceutical companies to protect study participants’ personal information…Certara2025年3月20日
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study Publication HIV感染でウイルス学的に抑制されている思春期患者における、長時間作用型注射剤カボテグラビルと長時間作用型注射剤リルピビリンの併用療法の安全性(IMPAACT 2017/MOCHA):第1/2相、多施設共同、オープンラベル、非比較、用量設定試験 The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…Danielle Pillsbury2025年3月20日
Anonymization vs. Redaction of Clinical Trial Data Blog Anonymization vs. Redaction of Clinical Trial Data 2025年1月17日 The vernacular for disclosing pharmaceutical clinical trial results to the public may…Certara2025年1月17日
Helping Sponsor Meet EMA Policy 0070 Requirements Case Study Helping Sponsor Meet EMA Policy 0070 Requirements The European Medicines Agency’s Policy on the Publication of Clinical Data for Medicinal Products for…Danielle Pillsbury2025年1月7日
Streamlining the Preparation of 1-Year and 2-Year PSURs Case Study Streamlining the Preparation of 1-Year and 2-Year PSURs We explore how we helped one client deliver a last-minute addition to a Periodic Safety…Danielle Pillsbury2024年12月18日
Delivering High-Quality, Timely Responses to EMA Safety Queries Case Study Delivering High-Quality, Timely Responses to EMA Safety Queries A pharmaceutical company approached us for support with eight safety-related queries from the European Medicines…Danielle Pillsbury2024年12月12日
CMC Writing Support Helps Client Lift Clinical Hold Case Study CMC Writing Supportはクライアントが臨床試験差し止めを回避するのに役立ちます In drug development, Chemistry, Manufacturing, and Controls (CMC) regulatory writing plays a pivotal role in ensuring the…Danielle Pillsbury2024年12月10日
A Medical Writer’s Guide to Collaborative Authoring Blog A Medical Writer’s Guide to Collaborative Authoring Once upon a time, regulatory writing for drug development programs followed a scheduled routine and…Certara2024年11月22日
FAQs on Developing EMA Policy 0070 Submissions Blog FAQs on Developing EMA Policy 0070 Submissions In September 2023, the European Medicines Agency (EMA) reinstated its Policy 0070 requirement to publish…Certara2024年11月1日
How To Respond to Health Authority Questions Blog How To Respond to Health Authority Questions Your biotech company has just submitted the marketing application for your first drug product. It’s…Certara2024年10月25日